Hualan Biological Engineering, Inc.

ACTIVE

No. A1, Quhualan Avenue, Hong Banner, 河南省新乡市, 河南省, Chinawww.hualanbio.comJoint Venture3,709 employeesEstablished: 1992-03-30$3.8B

Also known as:

hualan biological

hualan biological engineering

Clinical Trials

0 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1992

Overview

Trial Phase Distribution

Phase

Trials

Phase 3

55.6%

Not Applicable

11.1%

Phase 1

11.1%

Phase 2

11.1%

Phase 4

11.1%

Trial Status Distribution

Completed

100.0%

Clinical Trials

Trials sponsored by this organization (9)

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

Phase 4

Completed

interventional

Nov 20116,000 participants

Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)

Phase 3

Completed

interventional

Mar 2009810 participants

Page 1 of 2

Approvals

Approvals by Agency

NMPA

National Medical Products Administration

Approvals

Recent Approvals

Human Immunoglobulin for Intravenous Injection

NMPA

2026-04-15

Human Immunoglobulin for Intravenous Injection

NMPA

2026-04-15

Human Rabies Immunoglobulin

NMPA

2022-08-18

Human Rabies Immunoglobulin

Human Prothrombin Complex

NMPA

2020-05-14

Human Hepatitis B Immunoglobulin

NMPA

2020-05-14

Human Hepatitis B Immunoglobulin

News

No news articles found

Back to Organizations

Hualan Biological Engineering, Inc.

Overview

Trial Phase Distribution

Trial Status Distribution

Clinical Trials

Trials sponsored by this organization (9)

Phase IV Clinical Trial of an Inactivated Influenza Split Vaccine

Clinical Trial of the Inactivated Influenza Vaccine (0.25ml Formulation for Pediatric Use)

Post-marketing Clinical Observation of an Inactivated Influenza Split Vaccine

Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 003

Clinical Trial of Inactivated Influenza Vaccine (0.5ml Formulation)

Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 002

Clinical Trial of Group ACYW135 Meningococcal Polysaccharide Vaccine 001

评价人凝血因子Ⅸ在中重型血友病B（因子Ⅸ缺乏症）患者中按需治疗的有效性、安全性以及药代动力学特征

Approvals

Approvals by Agency

Recent Approvals

News